VSJ-110

DRUG3 trials

Sponsors

Vanda Pharmaceuticals

Conditions

Allergic ConjunctivitisDry Eye

Phase 2

Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

CompletedNCT04622345

Vanda PharmaceuticalsAllergic Conjunctivitis

Start: 2020-11-21End: 2021-06-28Updated: 2025-09-11

A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

RecruitingNCT06296966

Vanda PharmaceuticalsDry Eye

Start: 2024-02-29End: 2024-07-31Target: 40Updated: 2024-03-06

An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

RecruitingNCT07179055

Vanda PharmaceuticalsDry Eye

Start: 2025-10-31End: 2026-09-30Target: 160Updated: 2025-09-17